TDA may have a different list but what I have been following
Column 1 Column 2 Column 3 1 Development Name Type Indication 2 SAR339658 Anti-VLA 2 mAb Multiple Sclerosis 3 SAR228810 Anti-protofibrillar AB mAb Alzheimer’s disease 4 SAR252067 Anti-LIGHT mAb Crohn’s disease 5 Alirocumab PCSK9 mAb Cholesterol 6 SAR113244 Anti-CXCRS mAb Systemic lupus erythematosu 7 Dupilumab IL4RαmAbAtopic Dermatitis;
Asthma;
Nasal polyposis
Dupilumab has 3 target indications so you could almost count that as three. Though best leave it at one until you see some dosages for later stage trials being over 300mg which is not a bad rule of thumb cut off point for viscosity/volume/concentration exceeding PFS and AIDs capability
First cab off the rank is hopefully Alirocumab and Sanofi-REGN chasing Amgen and monthly dosing (Awaits reporting on Choice 1 program) Then its Dupilumab by my ruler
Guess with this in the bag UNS may let the cat out of the bag re Sanofi using Finesse for some of the drugs with as Sarilumab, Alirocumab etc. As you point out kar18na the announcement points a finger towards REGN
Good work to those loyal folk who hung around.
- Forums
- ASX - By Stock
- UNS
- New contract
New contract, page-23
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online